Skip to main content
SpringerLink
Log in

Aspects of quality of life on treatment with felodipine

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Quality of life has been assessed in a double-blind four week study comparing felodipine 5, 10, 20 mg and placebo added to metoprolol by adding two self-administered questionnaires to the conventional procedure for the evaluation of adverse events.

None of the aspects related to general well-being was affected by felodipine. The subjective symptoms reported were mostly dose-related and so here mainly observed at the highest dose. Some of them, e.g. headache, were transient.

It is concluded that felodipine in combination with metoprolol CR did not negatively influence the feeling of well-being of the patients. When the drug was given in low, individually adjusted doses, the symptoms normally associated with Ca antagonists were likely to be minimised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Baer P, Collins F, Bourianoff G, Ketchel M (1979) Assessing personality factors in essential hypertension with a brief self-report instrument. Psychosom Med 41: 321–329

    Google Scholar 

  • Bansal S (1988) Sexual dysfunction in hypertensive men. A critical review of the literature. Hypertension 12: 1–10

    Google Scholar 

  • Bengtsson C, Edström K, Furunes B, Sigurdsson JA, Tibblin G (1987) Prevalence of subjectively experienced symptoms in a population sample of women with special reference to women with arterial hypertension. Scand J Prim Health Care 5: 155–162

    Google Scholar 

  • Bergner M, Bobbitt RA, Carter WB, Gibson BS (1981) The Sickness Impact Profile: Development and final revision of a health status measure. Med Care 19: 787–805

    Google Scholar 

  • Brun J, Fröberg L, Kronmann P, Olsson L-B, Skoog P, Tygesen G, Bengtsson C, Scherstén B, Tibblin G (1990) Optimal felodipine dose when combined with metoprolol in arterial hypertension. J Cardiovasc Pharmacol 15 [Suppl 14]: 60–64 (in press)

    Google Scholar 

  • Bulpitt CJ, Dollery CT, Carne S (1976) Change in symptoms of hypertensive patients after referral to hospital clinic. Br Heart J 38: 121–128

    Google Scholar 

  • Cronbach LJ (1951) Coefficient alpha and the internal structure tests. Psychometrika 16: 297–334

    Google Scholar 

  • Croog S, Levine S, Sudilovsky A, Baume R, Clive J (1988) Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications Arch Intern Med 148: 788–794

    Google Scholar 

  • Daniels A, Opie L (1987) Monotherapy with the calcium channel antagonist Nisoldipine for systemic hypertension and comparison with diuretic drugs. Am J Cardiol 60: 703–707

    Google Scholar 

  • Dimenäs E, Dahlöf C, Jern S, Wiklund I, Defining quality of life in medicine (1991) Scand J Prim Health Care (in press)

  • Dimenäs E, Wiklund I, Dahlöf C, Lindvall K, Olofsson B, de Faire U (1989) Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 7: 885–890

    Google Scholar 

  • Dimenäs E, Dahlöf C, Olafsson B, Wiklund I (1991) An instrument for quantifying subjective symptoms among untreated and treated hypertensives. Development and documentation of the SSA-P. J Clin Res Pharmacoepidemiol (in press)

  • Dupuy HJ (1984) The Psychological General Well-Being (PGWB) Index, pp 170–183. In: Wenger NK, Mattson ME, Furberg CF, Elinson J (eds.) Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq Publ Inc, USA

    Google Scholar 

  • Elmfeldt D, Westerling S (1987) Aspects on the benefit-risk balance of felodipine in hypertension. Drugs 34 [Suppl 3]: 132–135

    Google Scholar 

  • Eriksson H, Svärdsudd K, Larsson B, Welin L, Ohlsson L-O, Tibblin G, Wilhelmsen L (1988) Quality of life in early heart failure. Scand J Prim Health Care 6: 161–167

    Google Scholar 

  • Friedman M, Bennet P (1977) Depression and hypertension. Psychosom Med 37: 134–142

    Google Scholar 

  • Furberg C, Schucker B, Chesney M (1984) Report of the working group. Mild hypertension. In: Wenger N (ed) Assessment of quality of life in clinical trials of cardiovascular therapies. Le Jacq Publ Inc, USA

    Google Scholar 

  • Guyatt G, Bombardier C, Tugwell PX (1986) Measuring disease-specific quality of life in clinical trials. Canad Med Assoc J 134: 889–895

    Google Scholar 

  • Guyatt G, Van Zanten S, Feeny D, Patrick D (1989) Measuring quality of life in clinical trials: a taxonomy and review. Canad Med Assoc J 140: 1441–1448

    Google Scholar 

  • Hansson L, Dahlöf B, Gudbrandsson T, Hellsing T, Kullman S, Kuylenstierna J, Leppert J, Möller B, Skogström K, Svensson A, Svensson O, Ugander L (1988) Antihypertensive effect of felodipine or hydralazine when added to β-blocker therapy. J Cardiovasc Pharmacol 12: 94–101

    Google Scholar 

  • Hedner T (1986) Calcium channel blockers: Spectrum of side effects and drug interactions. Acta Pharmacol Toxicol 58 [Suppl 2]: 119–130

    Google Scholar 

  • Jachuck SJ, Brierley H, Jachuck S, Willcox PM (1982) The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 32: 103–105

    Google Scholar 

  • Jenkins D, Stanton B-A, Niemcryk S, Rose R (1988) A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 41: 313–321

    Google Scholar 

  • Keidar S, Bienenboim D, Patant A (1982) Muscle cramps during treatment with nifedipine. Br Med J 285: 1241–1242

    Google Scholar 

  • Kennerfalk A Lundborg P, Wallander M-A (1990) Felodipine Safety Evaluation: Adverse Event Pattern. J Card Pharmacol 15 [Suppl 4]: S 106

  • Ljung B, Boström S-L, Hallbäck-Nordlander (1980) Vascular versus myocardial selectivity in vitro of H 154/82 — a new dihydropyridine. Blood Vessels 17: 154

    Google Scholar 

  • McCorvey E, Wright J, McKenney J, Proctor J (1989) Does antihypertensive therapy influence quality of life. Clin Pharm 8: 359–364

    Google Scholar 

  • Medical Research Council Working Party on Mild to Moderate Hypertension (1981) Adverse reactions to bendrofluazide and propranolol for treatment of mild hypertension. Lancet I: 539–542

    Google Scholar 

  • Meenan RF, Gertman PM, Mason JH (1980) Measuring health status in arthritis. The arthritis impact measurement scale. Arthritis Rheum 23: 146–152

    Google Scholar 

  • Miettinen OS (1987) Quality of life from the epidemiologic perspective. J Chron Dis 40: 641–643

    Google Scholar 

  • Miller L, Dalton M, Vestal R, Perkins G, Lyon G (1989) Quality of life. Methodological and regulatory/scientific aspects. J Clin Res Drug Develop 3: 117–128

    Google Scholar 

  • Nugent L, Miola S, Walker F (1987) Comparison of enalapril and metoprolol as initial therapy for mild to moderate hypertension. J Clin Pharmacol 27: 461–467

    Google Scholar 

  • Opie L (1988) Calcium Channel Antagonists, part IV: Side effects and contraindications, drug interactions and combinations. Cardiovasc Drugs and Therapy 2: 177–189

    Google Scholar 

  • Patrick DL, Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27 [Suppl]: S 217-S 232

    Google Scholar 

  • Rabkin J, Charles E, Kass F (1983) Hypertension and DSM-III depression in psychiatric outpatients. Am J Psychiatry 140: 1072–1074

    Google Scholar 

  • Rakel R (1987) Antihypertensive therapy and quality of life. Am Fam Physician 35: 221–226

    Google Scholar 

  • Reidenberg MM, Lowenthal DI (1968) Adverse non-drug reactions. N Engl Med 279: 678–679

    Google Scholar 

  • Saltiel E, Ellsodt AG, Monk IP, Langley MS (1988) Felodipine — A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 36: 387–428

    Google Scholar 

  • Salvetti A, Cardellino G, Pesenti M et al. (1989) Antihypertensive effect of slow-release nicardipine. A placebo-controlled crossover study. Eur J Clin Pharmacol 36: 439–442

    Google Scholar 

  • Sandberg A, Ragnarsson G, Johnsson UE, Sjögren J (1988) Design of a new multiple-unit controlled-release formulation of metoprolol CR. Eur J Clin Pharmacol 33 [Suppl 7]: 3–7

    Google Scholar 

  • Snedecor GW, Cochran WG (1980) Statistical Methods. Iowa State University Press, Ames Iowa, USA

    Google Scholar 

  • Tibblin G (1986) Kunskap om symptomens naturalhistoria — hjälp för läkarna i kontakten med patienten. Läkartidningen 83: 1186–1190

    Google Scholar 

  • Troidl H, Kusche J, Vestweber K-H, Engpasch E, Koeppen L, Bouillon B (1987) Quality of life: an important endpoint both in surgical practice and research. J Chron Dis 40: 523–528

    Google Scholar 

  • Vandenburg MJ, Evans SJW, Kelly BJ et al. (1984) Factors affecting the reporting of symptoms by hypertensive patients. Br J Clin Pharmacol 10: 189–195

    Google Scholar 

  • Veit C, Ware J (1983) The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 51: 730–742

    Google Scholar 

  • Wallander M, Palmer L (1986) A monitoring system for adverse rug experiences in a pharmaceutical company: the integration of preand postmarketing data. Drug Information Journal 20: 225–235

    Google Scholar 

  • Wallander M-A, Lundborg P (1989) Application of a new method for adverse experience monitoring to premarketing studies on two new drugs: some experiences. In: Edlavitch SA (ed) Pharmacoepidemiology, vol I. Lewis Publisher Inc, Chelsea Michigan, pp 163–169

    Google Scholar 

  • Wiklund I, Dimenäs E, Wahl M (1990) Factors of importance when evaluating quality of life in clinical trials. Controlled Clin Trials 11: 169–179

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Laboratories, AB Hässle, Mölndal, Sweden

    E. Dimenäs & M-A. Wallander

  2. Department of Family Medicine, Akademiska Hospital, Uppsala, Sweden

    M-A. Wallander & K. Svärdsudd

  3. Department of Medicine, Ostra Hospital, Gothenburg, Sweden

    E. Dimenäs & I. Wiklund

Authors
  1. E. Dimenäs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M-A. Wallander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Svärdsudd
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Wiklund
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dimenäs, E., Wallander, MA., Svärdsudd, K. et al. Aspects of quality of life on treatment with felodipine. Eur J Clin Pharmacol 40, 141–147 (1991). https://doi.org/10.1007/BF00280068

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00280068

Key words

Search

Navigation